Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial
Clinical Infectious Diseases · 08.02.2023 · 76 (3) · e10-e17
DOI: 10.1093/cid/ciac712 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 06.09.2022. Verfasst von Yoav Golan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tufts Medical Center, Appili Therapeutics, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Appili Therapeutics, Inc..
Abstract (Originalsprache)
Background
Despite vaccination, many remain vulnerable to coronavirus disease 2019 (COVID-19) and its complications. Oral antivirals to prevent COVID-19 progression are vital. Based on perceived potency and clinical efficacy, favipiravir is widely used to treat COVID-19. Evidence from large randomized controlled trials (RCT) is lacking.
Methods
In this multicenter double-blinded placebo-controlled RCT, adults with early mild-to-moderate COVID-19 were 1:1 randomized to favipiravir or placebo. The study evaluated time to sustained clinical recovery (TT-SCR), COVID-19 progression, and cessation of viral shedding.
Results
Of 1187 analyzed patients across 40 centers, 83.3% were Hispanic, 89.0% unvaccinated, 70.3% severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seronegative, and 77.8% had risk factors for COVID-19 progression. The median time from symptom presentation and from positive test to randomization was 3 and 2 days, respectively. There was no difference in TT-SCR (median of 7 days for both groups; P = .80), COVID-19 progression [11 patients each (1.9% vs 1.8%); P = .96], time to undetectable virus (median = 6 days, 95% confidence interval [CI] [6–8] vs 7 days, 95% CI [6-9]), or in undetectable virus by end of therapy (73.4% vs 72.3%; P = .94). Outcomes were consistent across the analyzed sub-groups. Adverse events were observed in 13.8% and 14.8% of favipiravir-treated and placebo-treated subjects, respectively. Uric acid elevation was more frequent among favipiravir-treated subjects (19.9% vs 2.8%).
Conclusions
Favipiravir was well tolerated but lacked efficacy in TT-SCR, progression to severe COVID-19, or cessation of viral shedding and should not be used to treat patients with COVID-19. (Supported by Appili Therapeutics) Clinical Trials Registration NCT04600895
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tufts Medical Center, Appili Therapeutics, Boston, Massachusetts, USA.
- Kohler and Milstein Research S.A. de C.V., Merida, Mexico.
- Rho, Inc, Durham, North Carolina, USA.
- Appili Therapeutics, Waterford, Virginia, USA.
- Quality Professional Healthcare, Miami, Florida, USA.
- Verus Clinical Research, Corp., Coconut Grove, Florida, USA.
Förderung
- Appili Therapeutics, Inc.
Zitieren
APA
Golan, Y., Campos, J. A. S., Woolson, R., Cilla, D., Hanabergh, R., Gonzales-Rojas, Y., Lopez, R., Finberg, R., & Balboni, A. (2023). Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial. Clinical Infectious Diseases, 76(3), e10-e17. https://doi.org/10.1093/cid/ciac712
Vancouver
Golan Y, Campos JAS, Woolson R, Cilla D, Hanabergh R, Gonzales-Rojas Y, et al. Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial. Clinical Infectious Diseases. 2023;76(3):e10-e17. doi:10.1093/cid/ciac712
BibTeX
@article{Golan2023,
author = {Golan, Yoav and Campos, Jesus Abraham Simon and Woolson, Rob and Cilla, Donald and Hanabergh, Rodolfo and Gonzales-Rojas, Yaneicy and Lopez, Reynaldo and Finberg, Robert and Balboni, Armand},
title = {Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {3},
pages = {e10--e17},
doi = {10.1093/cid/ciac712}
}
EUVIMED